301331.SZ
恩威医药
SZSE · C 制造业 · CN
CNY 21.84
−1.31%Year over year
Reported trailing growth
- Revenue
- +6.6%
- EBITDA
- —
- EBIT
- +1.5%
- EPS
- +5.0%
- Free cash flow
- -52.1%
- Operating cash flow
- -16.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +9.2%
- EBITDA
- -1.8%
- EBIT
- -8.7%
- Net income
- -8.5%
- EPS
- -24.9%
- Free cash flow
- +11.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026